These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 27318333

  • 21. Vancomycin therapy for severe Clostridium difficile-associated diarrhea.
    Huggan PJ, Murdoch DR.
    Clin Infect Dis; 2007 Dec 15; 45(12):1647-8; author reply 1649-51. PubMed ID: 18190330
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group.
    N Engl J Med; 2011 Feb 03; 364(5):422-31. PubMed ID: 21288078
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin.
    Wilcox MH, Howe R.
    J Antimicrob Chemother; 1995 Oct 03; 36(4):673-9. PubMed ID: 8591942
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.
    Carignan A, Poulin S, Martin P, Labbé AC, Valiquette L, Al-Bachari H, Montpetit LP, Pépin J.
    Am J Gastroenterol; 2016 Dec 03; 111(12):1834-1840. PubMed ID: 27619835
    [Abstract] [Full Text] [Related]

  • 28. Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
    Bishara J, Wattad M, Paul M.
    Clin Infect Dis; 2007 Dec 15; 45(12):1646-7; author reply 1649-51. PubMed ID: 18190329
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection.
    Lam SW, Bass SN, Neuner EA, Bauer SR.
    Int J Antimicrob Agents; 2013 Dec 15; 42(6):553-8. PubMed ID: 24103633
    [Abstract] [Full Text] [Related]

  • 31. Rifaximin in the treatment of recurrent Clostridium difficile infection.
    Mattila E, Arkkila P, Mattila PS, Tarkka E, Tissari P, Anttila VJ.
    Aliment Pharmacol Ther; 2013 Jan 15; 37(1):122-8. PubMed ID: 23095030
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections.
    Mullane K, Lee C, Bressler A, Buitrago M, Weiss K, Dabovic K, Praestgaard J, Leeds JA, Blais J, Pertel P.
    Antimicrob Agents Chemother; 2015 Mar 15; 59(3):1435-40. PubMed ID: 25534727
    [Abstract] [Full Text] [Related]

  • 34. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
    Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM, Polymer Alternative for CDI Treatment (PACT) investigators.
    Clin Infect Dis; 2014 Aug 01; 59(3):345-54. PubMed ID: 24799326
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Rifaximin Redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment.
    Johnson S, Schriever C, Patel U, Patel T, Hecht DW, Gerding DN.
    Anaerobe; 2009 Dec 01; 15(6):290-1. PubMed ID: 19698797
    [Abstract] [Full Text] [Related]

  • 38. Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.
    Louie T, Nord CE, Talbot GH, Wilcox M, Gerding DN, Buitrago M, Kracker H, Charef P, Cornely OA.
    Antimicrob Agents Chemother; 2015 Oct 01; 59(10):6266-73. PubMed ID: 26248357
    [Abstract] [Full Text] [Related]

  • 39. Impact of vancomycin faecal concentrations on clinical and microbiological outcomes in Clostridium difficile infection.
    Thabit AK, Nicolau DP.
    Int J Antimicrob Agents; 2015 Aug 01; 46(2):205-8. PubMed ID: 26055927
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.